Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-7,page-paged-7,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.5.0,vc_responsive

CLIENT NEWS

 

 

  • RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
    www.redhillbio.com
  • XPhyto builds commercial team to launch 25-minute COVID-19 RT-PCR test
    www.xphyto.com
  • CENTOGENE GmbH: CENTOGENE führt Studie zur Untersuchung des SARS-CoV-2-Infektionsrisikos im Öffentlichen Personen-Nahverkehr in Zusammenarbeit mit der Charité Research Organisation durch
    www.centogene.com
  • Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19
    www.marinomed.com
  • RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204
    www.redhillbio.com
  • CENTOGENE GmbH: Science Meets Culture: CENTOGENE’s Rare Disease Day 2021 Activities
    www.centogene.com
  • Marinomed Biotech AG publishes new supporting data on the in vitro efficacy of Carragelose® against SARS-CoV-2
    www.marinomed.com
  • RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
    www.redhillbio.com
  • Imcyse SA: Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round – Pfizer Joins as Newest Shareholder
    www.imcyse.com
  • DEBx Medical publishes first clinical data on novel desiccant gel for chemical debridement of infected, chronic wounds in peer-reviewed journal, Wounds
    www.debx-medical.com